Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Soins Pediatr Pueric ; (264): 23-4, 2012.
Article in French | MEDLINE | ID: mdl-22420077

ABSTRACT

Tuberculosis is one the world's biggest health problems. The prevention of this disease is adapted to the epidemiological situation and the economic constraints of each country. The correct treatment of patients as well as the care of people having been in contact with them are very effective methods which lead to the drop in the incidence and morbidity of tuberculosis.


Subject(s)
Mass Screening , Tuberculosis/prevention & control , Humans , Tuberculosis/diagnosis
2.
Cell Signal ; 24(5): 1093-9, 2012 May.
Article in English | MEDLINE | ID: mdl-22285804

ABSTRACT

Reduction of lung inflammation is one of the goals of cystic fibrosis (CF) therapy. Among anti-inflammatory molecules, glucocorticoids (GC) are one of the most prescribed. However, CF patients seem to be resistant to glucocorticoid treatment. Several molecular mechanisms that contribute to decrease anti-inflammatory effects of glucocorticoids have been identified in pulmonary diseases, but the molecular actions of glucocorticoids have never been studied in CF. In the cytoplasm, glucocorticoids bind to glucocorticoid receptor (GR) and then, control NF-κB and MAPK pathways through direct interaction with AP-1 and NF-κB in the nucleus. Conversely, MAPK can regulate glucocorticoid activation by targeting GR phosphorylation. Together these pathways regulate IL-8 release in the lung. Using bronchial epithelial cell lines derived from non CF and CF patients, we analyzed GR-based effects of glucocorticoids on NF-κB and MAPK pathways, after stimulation with TNF-α. We demonstrate that the synthetic glucocorticoid dexamethasone (Dex) significantly decreases IL-8 secretion, AP-1 and NF-κB activity in CF cells in a pro-inflammatory context. Moreover, we show that p38 MAPK controls IL-8 release by determining GR activation through specific phosphorylation on serine 211. Finally, we demonstrate a synergistic effect of dexamethasone treatment and inhibition of p38 MAPK inducing more than 90% inhibition of IL-8 production in CF cells. All together, these results demonstrate the good responsiveness to glucocorticoids of CF bronchial epithelial cells and the reciprocal link between glucocorticoids and p38 MAPK in the control of CF lung inflammation.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Bronchioles/pathology , Cystic Fibrosis/pathology , Dexamethasone/pharmacology , Epithelial Cells/drug effects , Glucocorticoids/pharmacology , Anisomycin/pharmacology , Cell Line , Enzyme Induction/drug effects , Humans , Inflammation , Interleukin-8/metabolism , NF-kappa B/metabolism , Phosphorylation , Protein Transport/drug effects , Receptors, Glucocorticoid/metabolism , Signal Transduction , Transcription Factor AP-1/metabolism , Transcriptional Activation , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , p38 Mitogen-Activated Protein Kinases/metabolism
3.
PLoS One ; 4(1): e4130, 2009.
Article in English | MEDLINE | ID: mdl-19125189

ABSTRACT

BACKGROUND: Development of T-cells based-Interferon gamma (IFNgamma) assays has offered new possibilities for the diagnosis of latent tuberculosis infection (LTBI) and active disease in adults. Few studies have been performed in children, none in France. With reference to the published data on childhood TB epidemiology in the Paris and Ile de France Region, we considered it important to evaluate the performance of IGRA (QuantiFERON TB Gold In Tube(R), QF-TB-IT) in the diagnosis and the follow-up through treatment of LTBI and active TB in a cohort of French children. METHODOLOGY/PRINCIPAL FINDINGS: 131 children were recruited during a prospective and multicentre study (October 2005 and May 2007; Ethical Committee St Louis Hospital, Paris, study number 2005/32). Children were sampled at day 0, 10, 30, 60 (except Healthy Contacts, HC) and 90 for LTBI and HC, and a further day 120, and day 180 for active TB children. Median age was 7.4 years, with 91% of the children BCG vaccinated. LTBI and active TB children undergoing therapy produced significant higher IFNgamma values after 10 days of treatment (p = 0.035). In addition, IFNgamma values were significantly lower at the end of treatment compared to IFNgamma values at day 0, although the number of positive patients was not significantly different between day 0 and end of treatment. CONCLUSIONS/ SIGNIFICANCE: By following quantitative IFNgamma values in each enrolled child with LTBI or active TB and receiving treatment, we were able to detect an increase in the IFNgamma response at day 10 of treatment which might allow the confirmation of a diagnosis. In addition, a decline in IFNgamma values during treatment makes it possible for clinicians to monitor the effect of preventive or curative therapy.


Subject(s)
Interferon-gamma , Tuberculosis/diagnosis , Tuberculosis/immunology , Adolescent , Adult , BCG Vaccine/immunology , Child , Child, Preschool , Female , France/epidemiology , Humans , Infant , Infant, Newborn , Interferon-gamma/immunology , Male , Prospective Studies , ROC Curve , Reagent Kits, Diagnostic , Time Factors , Tuberculosis/epidemiology , Tuberculosis/prevention & control
4.
Pediatr Pulmonol ; 43(12): 1224-32, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19009622

ABSTRACT

The clinical course of cystic fibrosis (CF) varies considerably among patients carrying the same CF-causing gene mutation. Additional genetic modifiers may contribute to this variability. As airway inflammation is a key component of CF pathophysiology, we investigated whether major cytokine variants represent such modifiers in young CF patients. We tested 13 polymorphisms in 8 genes that play a key role in the inflammatory response: tumor necrosis factor, lymphotoxin alpha, interleukin (IL) 1B, IL1 receptor antagonist, IL6, IL8, IL10 and transforming growth factor beta 1 (TGFB1), for an association with lung disease progression and nutritional status in 329 CF patients. Variants in the TGFB1 gene at position +869T/C demonstrated a significant association with lung function decline. A less pronounced rate of decline in forced expiratory volume in 1 sec (FEV(1)) and forced vital capacity (FVC) were observed in patients heterozygous for TGFB1 +869 (+869CT), when compared to patients carrying either TGFB1 +869TT or +869CC genotypes. These findings support the concept that TGFB1 gene variants appear to be important genetic modifiers of lung disease progression in CF.


Subject(s)
Cystic Fibrosis/genetics , Inflammation Mediators/metabolism , Adolescent , Child , Disease Progression , Female , Genetic Variation , Humans , Interleukin-1/genetics , Interleukin-10/genetics , Interleukin-6/genetics , Interleukin-8/genetics , Lymphotoxin-alpha/genetics , Male , Transforming Growth Factor beta1/genetics , Tumor Necrosis Factor-alpha/genetics
5.
Eur J Pediatr ; 167(10): 1203-7, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18202853

ABSTRACT

We report a case of a 13-year-old girl with an asymptomatic isoniazid-resistant tuberculosis contact. Six months after the contact had been made, chest radiography showed left upper lobe infiltrates without hilar lymphadenopathy, which led to the start of an antituberculous treatment. Tuberculin skin test remained negative and blood tests showed hypereosinophilia. One month after the onset of the treatment, she presented with asthenia, weight loss, and cough. She was admitted to our unit with a diagnosis of drug-resistant tuberculosis. Blood tests showed the persistence of hypereosinophilia. Chest radiograph and high-resolution lung computed tomography (CT) scan showed alveolar peripheral condensations on both upper lobes without significant hilar lymphadenopathy. Bronchoalveolar lavage (BAL) showed a normal total cell count with 44% of eosinophils. Microbiological analyses were all negative. Chronic eosinophilic pneumonia (CEP) was confirmed after the elimination of other different eosinophilic lung diseases. The patient was highly responsive to high doses of oral corticosteroids. Dyspnoea and cough disappeared within one week and chest CT scan showed regression of the lung infiltrates within one month. No relapse occurred during the following nine months.


Subject(s)
Pulmonary Eosinophilia/diagnosis , Adolescent , Diagnosis, Differential , Female , Humans , Tuberculosis, Multidrug-Resistant/diagnosis
6.
Respir Res ; 8: 88, 2007 Nov 29.
Article in English | MEDLINE | ID: mdl-18047640

ABSTRACT

BACKGROUND: The variability in the inflammatory burden of the lung in cystic fibrosis (CF) patients together with the variable effect of glucocorticoid treatment led us to hypothesize that glucocorticoid receptor (GR) gene polymorphisms may affect glucocorticoid sensitivity in CF and, consequently, may contribute to variations in the inflammatory response. METHODS: We evaluated the association between four GR gene polymorphisms, TthIII, ER22/23EK, N363S and BclI, and disease progression in a cohort of 255 young patients with CF. Genotypes were tested for association with changes in lung function tests, infection with Pseudomonas aeruginosa and nutritional status by multivariable analysis. RESULTS: A significant non-corrected for multiple tests association was found between BclI genotypes and decline in lung function measured as the forced expiratory volume in one second (FEV1) and the forced vital capacity (FVC). Deterioration in FEV1 and FVC was more pronounced in patients with the BclI GG genotype compared to the group of patients with BclI CG and CC genotypes (p = 0.02 and p = 0.04 respectively for the entire cohort and p = 0.01 and p = 0.02 respectively for F508del homozygous patients). CONCLUSION: The BclI polymorphism may modulate the inflammatory burden in the CF lung and in this way influence progression of lung function.


Subject(s)
Cystic Fibrosis/genetics , Cystic Fibrosis/physiopathology , Lung Diseases/physiopathology , Polymorphism, Genetic , Receptors, Glucocorticoid/genetics , Adolescent , Child , Cohort Studies , Deoxyribonucleases, Type II Site-Specific , Disease Progression , Female , Genotype , Haplotypes , Humans , Lung Diseases/microbiology , Male , Pseudomonas Infections , Respiratory Function Tests
7.
Biochem Biophys Res Commun ; 357(2): 402-7, 2007 Jun 01.
Article in English | MEDLINE | ID: mdl-17420005

ABSTRACT

Transcription nuclear factor-kappaB (NF-kappaB) is hyperactivated in cystic fibrosis (CF) lung epithelial cells, and participates in exaggerated IL-8 production in the CF lung. We recently found that rapid activation of NF-kappaB occurred in a CF lung epithelial IB3-1 cell line (CF cells) upon IL-1beta stimulation, which was not observed in its CFTR-corrected lung epithelial S9 cell line (corrected cells). To test whether other signaling pathways such as that of mitogen-activated protein kinases (MAPKs) could be involved in IL-1beta-induced IL-8 production of CF cells, we investigated ERK1/2, JNK, and p38MAP signaling compared to NF-kappaB. Within 30min, exposure to IL-1beta caused high activation of NF-kappaB, ERK1/2, p38MAP but not JNK in CF cells compared to corrected cells. Treatment of IL-1beta-stimulated CF cells with a series of chemical inhibitors of NF-kappaB, ERK1/2, and p38MAP, when used separately, reduced slightly IL-8 production. However, when used together, these inhibitors caused a blockade in IL-1beta-induced IL-8 production in CF cells. Understanding of the cross-talk between NF-kappaB and MAPKs signaling in CF lung epithelial cells may help in developing new therapeutics to reduce lung inflammation in patients with CF.


Subject(s)
Cystic Fibrosis/metabolism , Epithelial Cells/metabolism , Interleukin-1beta/administration & dosage , Interleukin-8/metabolism , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B p50 Subunit/metabolism , Respiratory Mucosa/metabolism , Cell Line , Dose-Response Relationship, Drug , Epithelial Cells/drug effects , Humans , Lung/drug effects , Lung/metabolism , Respiratory Mucosa/drug effects , Signal Transduction/drug effects
8.
Am J Physiol Lung Cell Mol Physiol ; 290(3): L588-96, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16272177

ABSTRACT

Persistent presence of PMN in airways is the hallmark of CF. Our aim was to assess PMN adherence, percentage of apoptotic airway PMN (aPMN), and IL-6 and IL-8 production when aPMN are in contact with airway epithelial cells. Before coculture, freshly isolated CF aPMN have greater spontaneous and TNF-alpha-induced apoptosis compared with blood PMN from the same CF patients and from aPMN of non-CF patients. We then examined cocultures of PMN isolated from CF and non-CF airways with bronchial epithelial cells bearing mutated cftr compared with cftr-corrected bronchial epithelial cells. After 18-h coculture, the number of CF aPMN adhered on cftr-deficient bronchial epithelial cells was 2.3-fold higher compared with the coculture of non-CF aPMN adhered on cftr-corrected bronchial epithelial cells. The percentage of CF apoptotic aPMN (9.5 +/- 0.2%) adhered on cftr-deficient bronchial epithelial cells was similar to the percentage of non-CF apoptotic aPMN adhered on cftr-corrected bronchial epithelial cells (10.3 +/- 0.7%). IL-6 and IL-8 levels were enhanced 6.5- and 2.9-fold, respectively, in coculture of CF aPMN adhered on cftr-deficient bronchial epithelial cells compared with coculture of non-CF aPMN adhered on cftr-corrected bronchial epithelial cells. Moreover, blocking surface adhesion molecules ICAM-1, VCAM-1, and E-selectin on cftr-deficient bronchial epithelial cells with specific MAbs inhibited the adherence of CF aPMN by 64, 51, and 50%, respectively. Our data suggest that in CF patients a high number of nonapoptotic PMN adhered on airway epithelium associated with elevated IL-6 and IL-8 levels may contribute to sustained and exaggerated inflammatory response in CF airways.


Subject(s)
Cell Adhesion , Cystic Fibrosis Transmembrane Conductance Regulator/pharmacology , Epithelial Cells/metabolism , Interleukin-6/metabolism , Interleukin-8/metabolism , Neutrophils/metabolism , Adolescent , Adult , Antibodies, Monoclonal/pharmacology , Apoptosis , Bronchi/cytology , Bronchi/metabolism , Case-Control Studies , Cell Communication , Child, Preschool , Coculture Techniques , Cystic Fibrosis Transmembrane Conductance Regulator/deficiency , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , E-Selectin/chemistry , E-Selectin/immunology , E-Selectin/metabolism , Female , Humans , Intercellular Adhesion Molecule-1/chemistry , Intercellular Adhesion Molecule-1/immunology , Intercellular Adhesion Molecule-1/metabolism , Male , Vascular Cell Adhesion Molecule-1/chemistry , Vascular Cell Adhesion Molecule-1/immunology , Vascular Cell Adhesion Molecule-1/metabolism
9.
J Infect Dis ; 191(11): 1988-91, 2005 Jun 01.
Article in English | MEDLINE | ID: mdl-15871134

ABSTRACT

Recent evidence suggests that genetic polymorphisms that affect the production of interleukin (IL)-10 may play a role in the response to pathogens in cystic fibrosis (CF). The present study was designed to investigate a possible association between alleles carried at position -1082 in the promoter region of the IL-10 gene and clinical data on 378 patients with CF. After adjustment for potential confounding variables, a significant relationship was found between the -1082GG genotype and both colonization with Aspergillus fumigatus and allergic bronchopulmonary aspergillosis. In addition, higher serum levels of IL-10 were observed in patients colonized with A. fumigatus. These results suggest that polymorphisms in the promoter region of the IL-10 gene may influence the host response to A. fumigatus in the context of CF.


Subject(s)
Aspergillosis/immunology , Aspergillus fumigatus , Cystic Fibrosis/immunology , Interleukin-10/genetics , Lung Diseases, Fungal/immunology , Polymorphism, Genetic/immunology , Adolescent , Child , Child, Preschool , Cystic Fibrosis/genetics , Cystic Fibrosis/microbiology , Humans
10.
Am J Physiol Lung Cell Mol Physiol ; 284(6): L997-1003, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12547728

ABSTRACT

Inflammation plays a critical role in lung disease progression in cystic fibrosis (CF). This inflammatory process is dominated by a neutrophil influx in the airways. To determine whether the accumulation of neutrophils in the airways of CF patients is associated with an altered function, we analyzed the capacity of neutrophils isolated from the lung compartment and the blood to release the major neutrophil pro- and anti-inflammatory cytokines IL-8 and IL-1-receptor antagonist (ra) spontaneously and in the presence of LPS. Comparison of cytokine production by blood neutrophils from CF patients and from control subjects showed significantly increased IL-8 and decreased IL-1ra release by CF neutrophils. Comparison of cytokine production by airway and blood neutrophils from CF patients also documented distinct profiles: the spontaneous release of IL-8 and IL-1ra by airway neutrophils was significantly higher than that from blood neutrophils. Culture in the presence of LPS failed to further enhance cytokine production. Analysis of the effect of dexamethasone confirmed the difference in the responsiveness of lung and blood neutrophils in CF. Used at a concentration effective in reducing IL-8 production by blood neutrophils, dexamethasone (10(-6) M) was unable to repress secretion of IL-8 by airway neutrophils. In addition, comparison of cytokine production by airway neutrophils from children with CF and children with dyskinetic cilia syndrome also documented distinct profiles of secretion. These results are consistent with a dysregulated cytokine production by lung and blood neutrophils in CF. They provide support to the hypothesis that not only the CF genotype but also the local environment may modify the functional properties of the neutrophils.


Subject(s)
Cystic Fibrosis/immunology , Interleukin-8/biosynthesis , Lung/cytology , Neutrophils/metabolism , Sialoglycoproteins/biosynthesis , Adolescent , Cells, Cultured , Child , Cystic Fibrosis/metabolism , Dexamethasone/pharmacology , Female , Glucocorticoids/pharmacology , Humans , Interleukin 1 Receptor Antagonist Protein , Interleukin-8/metabolism , Lung/immunology , Male , Neutrophils/cytology , Pneumonia/immunology , Pneumonia/metabolism , Sialoglycoproteins/metabolism
11.
Hepatology ; 36(4 Pt 1): 913-7, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12297838

ABSTRACT

Liver disease in patients with cystic fibrosis (CF) is inconstant and has not yet been clearly related to any specific risk factor. While the expression of cystic fibrosis transmembrane conductance regulator (CFTR) is restricted to the biliary epithelium in the liver, recent findings indicate that CFTR modulates reduced glutathione (GSH) transport and that CFTR dysfunction creates an imbalance in the antioxidant defense. Among liver detoxifying enzymes, the glutathione S-transferases (GSTs) play a key role in the protection against oxidative stress. Because oxidative injury contributes to the development of liver disease, we hypothesized that 2 members of the GST superfamily, GSTM1 and GSTP1, which are expressed in the biliary epithelium, could influence the hepatic status in patients with CF. The potential impact of GSTM1 and GSTP1 gene polymorphisms was assessed in 106 children with CF (mean age, 11.5 years). Based on polymerase chain reaction/restriction fragment length polymorphism analysis, we found that the frequency of GSTP1-Ile(105)/Ile(105) genotype was significantly higher in patients with CF with liver disease than in those without (P <.03). Among the youngest patients, aged 6 years, GSTP1-Ile(105)/Ile(105) genotype was associated with a 8-fold increase in the risk of liver disease compared with other GSTP1 genotypes (P =.002). No association between the GSTM1 genotype and liver status was documented. In conclusion, GSTP1-Ile(105)-encoding allele contributes to hepatic dysfunction in CF. Identification of this polymorphism may have prognostic value and prompt early treatment in patients with CF with an increased risk of liver disease.


Subject(s)
Cystic Fibrosis/epidemiology , Cystic Fibrosis/genetics , Glutathione Transferase/genetics , Isoenzymes/genetics , Liver Diseases/epidemiology , Liver Diseases/genetics , Polymorphism, Single Nucleotide , Adolescent , Child , Female , Genetic Predisposition to Disease/epidemiology , Genotype , Glutathione S-Transferase pi , Humans , Male , Risk Factors
12.
Am J Physiol Lung Cell Mol Physiol ; 282(4): L863-71, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11880314

ABSTRACT

Tumor necrosis factor (TNF)-alpha is a key molecule in lung inflammation. We have established the insulin-like growth factor binding protein 2 (IGFBP-2) as a marker associated with the growth arrest of lung alveolar epithelial cells (AEC). Here, we studied the effects of TNF-alpha on AEC proliferation and the putative protective role of retinoic acid (RA). We documented an antiproliferative action of TNF-alpha that was reversible only at 24 h and then became irreversible with induction of apoptosis. TNF-alpha treatment was associated with a dramatic induction of IGFBP-2. To discover the mechanism of action of IGFBP-2, we further tested the mitogenic potential of IGF-I to counteract TNF-alpha inhibition. Addition of IGF-I to the TNF-alpha containing medium did not stimulate proliferation, whereas des(1-3)IGF-I, an analog of IGF-I that bears low affinity for IGFBPs, was able to restore cell growth. Interestingly, we observed that RA abrogated TNF-alpha-induced growth arrest and that this effect was associated with a dramatic decrease in IGFBP-2 expression. These results suggest a protective role of RA from TNF-alpha antiproliferative action, through mechanisms involving modulation of IGFBP-2 production.


Subject(s)
Antineoplastic Agents/pharmacology , Respiratory Mucosa/drug effects , Tretinoin/pharmacology , Tumor Necrosis Factor-alpha/pharmacology , Animals , Cell Division/drug effects , Cell Division/immunology , Cell Line , Drug Interactions , Epithelial Cells/cytology , Epithelial Cells/drug effects , Insulin-Like Growth Factor Binding Protein 2/metabolism , Insulin-Like Growth Factor I/pharmacology , Peptide Fragments/pharmacology , Pneumonia/drug therapy , Pulmonary Alveoli/cytology , Rats , Respiratory Mucosa/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...